BIOMAT Database Logo BIOMAT Database Logo

Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. 2014

Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg, Faculté de Médecine, Université de Strasbourg, Strasbourg, France binsu.paris7@gmail.com c.moog@unistra.fr.

Plasmacytoid dendritic cells (pDC) poorly replicate human immunodeficiency virus type 1 (HIV-1) but efficiently transfer HIV-1 to adjacent CD4 T lymphocytes. We found that coculture with T lymphocytes downregulates SAMHD1 expression, enhances HIV-1 replication, and increases pDC maturation and alpha interferon (IFN-α) secretion. HIV-1 transfer to T lymphocytes is inhibited by broadly neutralizing antibody VRC01 with efficiency similar to that of cell-free infection of T lymphocytes. Interestingly, prevention of HIV-1 transmission by VRC01 retains IFN-α secretion. These results emphasize the multiple functions of VRC01 in protection against HIV-1 acquisition.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080908 Broadly Neutralizing Antibodies Neutralizing antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent (e.g., HIV) by targeting several epitopes. Broad Neutralizing Antibodies,Broad Neutralizing Antibody,Broad Spectrum Antibodies,Broadly Neutralizing Antibody,Cross-Neutralizing Antibodies,Cross-Neutralizing Antibody,bnAb,bnAbs,Antibodies, Broad Neutralizing,Antibodies, Broad Spectrum,Antibodies, Broadly Neutralizing,Antibodies, Cross-Neutralizing,Antibody, Broad Neutralizing,Antibody, Broadly Neutralizing,Antibody, Cross-Neutralizing,Cross Neutralizing Antibodies,Cross Neutralizing Antibody,Neutralizing Antibodies, Broad,Neutralizing Antibodies, Broadly,Neutralizing Antibody, Broad,Neutralizing Antibody, Broadly,Spectrum Antibodies, Broad
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies.
June 2018, AIDS (London, England),
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
September 2011, Journal of virology,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
December 2015, Science translational medicine,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
January 2018, Advances in experimental medicine and biology,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Cell-to-Cell Transmission of HIV-1 and HIV-2 from Infected Macrophages and Dendritic Cells to CD4+ T Lymphocytes.
April 2023, Viruses,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01.
January 2021, Frontiers in immunology,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.
July 2017, mAbs,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
January 2024, Proceedings of the National Academy of Sciences of the United States of America,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells.
June 2005, The Journal of experimental medicine,
Bin Su, and Alexandre Lederle, and Géraldine Laumond, and Camille Ducloy, and Sylvie Schmidt, and Thomas Decoville, and Christiane Moog
Extracellular ATP reduces HIV-1 transfer from immature dendritic cells to CD4+ T lymphocytes.
March 2008, Retrovirology,
Copied contents to your clipboard!